Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803610 | 0.94 | EPHX1 (0.67) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL31700886 | 0.90 | EPHX1 (0.55) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL671402 | 0.90 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL2500606 | 0.90 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL189361 | 0.90 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL2495441 | 0.88 | EPHX1 (0.56) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL31554756 | 0.88 | EPHX1 (0.60) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL2500609 | 0.88 | EPHX1 (0.56) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL22759160 | 0.86 | EPHX1 (0.61) | EPHX1ALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL743999 | 0.86 | EPHX1 (0.65) | EPHX1ALDH1A1HPGDMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119060026-A | Benzyl piperidine-containing formononetin derivative and preparation method and application thereof | 贵州大学 | 2024-12-03 | — | — | CN | claimed |
| US-12063930-B2 | Sulfonamide-containing 4-(N-methyl) aminopiperidine myricetin derivatives, preparation method and application | GUIZHOU UNIVERSITY (CN) | 2024-08-20 | — | — | US | claimed |
| CN-117645567-A | Chalcone derivative containing piperidine sulfonamide structure, and preparation method and application thereof | 贵州大学 | 2024-03-05 | — | — | CN | claimed |
| US-20230131193-A1 | SULFONAMIDE-CONTAINING 4-(N-METHYL) AMINOPIPERIDINE MYRICETIN DERIVATIVES, PREPARATION METHOD AND APPLICATION | GUIZHOU UNIVERSITY (CN) | 2023-04-27 | — | — | US | claimed |
| EP-4747243-A1 | LIGANDS AND COMPOSITIONS AND METHODS OF USE THEREOF | Baylor College of Medicine (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-0507861-B1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | UPJOHN CO (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5489593-A | Anti-aids piperazines | THE UPJOHN COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0686642-A2 | Modified guanidino and amidino thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-12-13 | — | — | EP | disclosed |
| CN-1109468-A | Sulfonamido heterocyclic thrombin inhibitors | BRISTOL MYERS SQIBB COMPANY (US) | 1995-10-04 | — | — | CN | disclosed |
| EP-0601459-A2 | Sulfonamido heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993001181-A1 | SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS | THE UPJOHN COMPANY (US) | 1993-01-21 | — | — | WO | disclosed |
| EP-0507861-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS. | UPJOHN CO (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1991009849-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | EPHX1 1977/4885ALDH1A1 2085/4885HPGD 2098/4885 |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | EPHX1 4229/4885ALDH1A1 1213/4885HPGD 2503/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | EPHX1 4116/4885ALDH1A1 3543/4885HPGD 4182/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | EPHX1 3918/4885ALDH1A1 2758/4885HPGD 2757/4885 |
| US-12063930-B2 | Sulfonamide-containing 4-(N-methyl) aminopiperidine myricetin derivatives, preparation method and application | NISCH, SMYD2, NSD2 | EPHX1 4223/4885ALDH1A1 4036/4885HPGD 4154/4885 |
| US-20230131193-A1 | SULFONAMIDE-CONTAINING 4-(N-METHYL) AMINOPIPERIDINE MYRICETIN DERIVATIVES, PREPARATION METHOD AND APPLICATION | NISCH, SMYD2, NSD2 | EPHX1 4223/4885ALDH1A1 4036/4885HPGD 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.